Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$0.12 - $0.69 $334 - $1,925
2,790 Added 0.41%
689,982 $82,000
Q4 2022

Feb 13, 2023

BUY
$0.23 - $0.34 $305 - $452
1,330 Added 0.19%
687,192 $199,000
Q3 2022

Nov 14, 2022

SELL
$0.35 - $0.72 $118,908 - $244,612
-339,739 Reduced 33.13%
685,862 $253,000
Q2 2022

Aug 12, 2022

SELL
$0.38 - $2.58 $110,320 - $749,015
-290,316 Reduced 22.06%
1,025,601 $572,000
Q1 2022

May 12, 2022

SELL
$2.27 - $3.62 $133,591 - $213,040
-58,851 Reduced 4.28%
1,315,917 $2.99 Million
Q4 2021

Feb 10, 2022

BUY
$2.11 - $3.0 $44,158 - $62,784
20,928 Added 1.55%
1,374,768 $3.67 Million
Q3 2021

Nov 09, 2021

BUY
$2.21 - $2.89 $7,237 - $9,464
3,275 Added 0.24%
1,353,840 $3.17 Million
Q2 2021

Aug 11, 2021

BUY
$2.39 - $3.5 $3.23 Million - $4.73 Million
1,350,565 New
1,350,565 $3.82 Million

About Aptinyx Inc.


  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.